The transition from C1 or C3 to C2 may explain the significant immune activation that occurred in CD74-lo group (Fig. 3b) and further support that AK104 therapy efficiently altered the tumor immune microenvironment and increased immune cell infiltration (Fig. 3d, Supplementary Fig. 4b). Here, CD74 is linked to neoplasm.